tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NUVL Stock Latest News

Nuvalent presents data from ARROS-1 trial of zidesamtinib
The FlyNuvalent presents data from ARROS-1 trial of zidesamtinib
21h ago
NUVL
Nuvalent’s Promising Oncology Pipeline Drives Buy Rating with $111 Price Target
PremiumRatings
Nuvalent’s Promising Oncology Pipeline Drives Buy Rating with $111 Price Target
4d ago
NUVL
Nuvalent assumed with a Buy at Guggenheim
PremiumThe Fly
Nuvalent assumed with a Buy at Guggenheim
4d ago
NUVL
Nuvalent assumed with a Buy at Guggenheim
PremiumThe Fly
Nuvalent assumed with a Buy at Guggenheim
5d ago
NUVL
Nuvalent initiated with an Outperform at Raymond James
PremiumThe Fly
Nuvalent initiated with an Outperform at Raymond James
6d ago
NUVL
Nuvalent initiated with an Overweight at Piper Sandler
PremiumThe FlyNuvalent initiated with an Overweight at Piper Sandler
20d ago
NUVL
Nuvalent Reports Q2 2025 Financials and Pipeline Progress
Premium
Company Announcements
Nuvalent Reports Q2 2025 Financials and Pipeline Progress
1M ago
NUVL
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
Premium
Ratings
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
1M ago
NUVL
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating
1M ago
NUVL
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
PremiumThe Fly
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
1M ago
NUVL
Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating
PremiumRatings
Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating
2M ago
NUVL
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial
PremiumCompany Announcements
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial
2M ago
8K
NUVL
Nuvalent doses first patient in Alkazar trial
PremiumThe FlyNuvalent doses first patient in Alkazar trial
2M ago
NUVL
Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
Premium
Ratings
Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
2M ago
NUVL
Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
Premium
The Fly
Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
2M ago
NUVL
Nuvalent price target raised to $112 from $105 at Baird
PremiumThe Fly
Nuvalent price target raised to $112 from $105 at Baird
3M ago
NUVL
Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
PremiumRatings
Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
3M ago
NUVL
Nuvalent price target raised to $140 from $125 at Leerink
PremiumThe Fly
Nuvalent price target raised to $140 from $125 at Leerink
3M ago
NUVL
Nuvalent price target raised to $130 from $110 at H.C. Wainwright
PremiumThe Fly
Nuvalent price target raised to $130 from $110 at H.C. Wainwright
3M ago
NUVL
Nuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile
PremiumRatingsNuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile
3M ago
NUVL
Nuvalent Announces Positive Data for Zidesamtinib Trial
Premium
Company Announcements
Nuvalent Announces Positive Data for Zidesamtinib Trial
3M ago
8K
NUVL
Nuvalent Announces New Director and Annual Meeting Results
Premium
Company Announcements
Nuvalent Announces New Director and Annual Meeting Results
3M ago
8K
NUVL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >